» Articles » PMID: 6777774

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating Hormone: a Highly Potent Alpha-melanotropin with Ultralong Biological Activity

Overview
Specialty Science
Date 1980 Oct 1
PMID 6777774
Citations 159
Authors
Affiliations
Soon will be listed here.
Abstract

alpha-Melanocyte-stimulating hormone (alpha-MSH) reversibly darkens frog skins by stimulating melanosome movement (dispersion) within melanophores. Heat-alkali treatment of alpha-MSH results in prolonged biological activity of the hormone. Quantitative gas chromatographic analysis of the hydrolyzed heat-alkali-treated peptide revealed partial racemization particularly at the 4(methionine) and 7(phenylalanine) positions. [Nle4]-alpha-MSH, a synthetic analogue of alpha-MSH, reversibly darkens frog skins and also exhibits prolonged activity after heat-alkali treatment. Synthesis of [Nle4, D-Phe7]-alpha-MSH provided an analogue with prolonged biological activity identical to that observed with heat-alkali-treated alpha-MSH or [Nle4]-alpha-MSH. [Nle4, D-Phe7]-alpha-MSH was resistant to enzymatic degradation by serum enzymes. In addition, this peptide exhibited dramatically increased biological activity as determined by frog skin bioassay, activation of mouse melanoma adenylate cyclase, and stimulation of mouse melanoma cell tyrosinase activity. This Nle4, D-Phe7 synthetic analogue of alpha-MSH is a very porent melanotropin, 26 times as potent as alpha-MSH in the adenylate cyclase assay. The resistance of the peptide to enzymatic degradation and its extraordinarily potent and prolonged biological activity should make this analogue of alpha-MSH an important molecular probe for studying the melanotropin receptors of both normal and abnormal (melanoma) melanocytes.

Citing Articles

Anti-inflammatory treatment using alpha melanocyte stimulating hormone (α-MSH) does not alter osteoblasts differentiation and fracture healing.

Graue J, Timmen M, Schmitz K, Kronenberg D, Bohm M, Sivaraj K BMC Musculoskelet Disord. 2025; 26(1):123.

PMID: 39915758 PMC: 11800508. DOI: 10.1186/s12891-025-08374-9.


Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).

Weirath N, Haskell-Luevano C ACS Pharmacol Transl Sci. 2024; 7(9):2706-2724.

PMID: 39296259 PMC: 11406693. DOI: 10.1021/acsptsci.4c00129.


An overview of benefits and risks of chronic melanocortin-1 receptor activation.

Bohm M, Robert C, Malhotra S, Clement K, Farooqi S J Eur Acad Dermatol Venereol. 2024; 39(1):39-51.

PMID: 39082868 PMC: 11664455. DOI: 10.1111/jdv.20269.


Journey through the spectacular landscape of melanocortin 1 receptor.

Upadhyay P, Swope V, Starner R, Koikov L, Abdel-Malek Z Pigment Cell Melanoma Res. 2024; 37(5):667-680.

PMID: 38857302 PMC: 11479856. DOI: 10.1111/pcmr.13180.


Afamelanotide in protoporphyria and other skin diseases: a review.

Polanska A, Wegner J, Nutbohm P, Staubach P, Zaba R, Danczak-Pazdrowska A Postepy Dermatol Alergol. 2024; 41(2):149-154.

PMID: 38784937 PMC: 11110213. DOI: 10.5114/ada.2024.138818.


References
1.
Pollock G, FROMMHAGEN L . The extent of racemization of some amino acids in dilute alkali-treated protein and soil humic and fulvic acid. Anal Biochem. 1968; 24(1):18-26. DOI: 10.1016/0003-2697(68)90055-9. View

2.
Bregman M, Sawyer T, Hadley M, Hruby V . Adenosine and divalent cation effects on S-91 melanoma adenylate cyclase. Arch Biochem Biophys. 1980; 201(1):1-7. DOI: 10.1016/0003-9861(80)90480-4. View

3.
Silman R, Chard T, LANDON J, Lowry P, Smith I, Young I . ACTH and MSH peptides in the human adult and fetal pituitary gland. Front Horm Res. 1977; 4:179-87. DOI: 10.1159/000400364. View

4.
Lemaire S, Yamashiro D, Li C . Synthesis and biological activity of camel and bovine beta-melanotropins. J Med Chem. 1976; 19(3):373-6. DOI: 10.1021/jm00225a006. View

5.
Pert C, Pert A, Chang J, Fong B . (D-Ala2)-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. Science. 1976; 194(4262):330-2. DOI: 10.1126/science.968485. View